Abstract
Multiple sclerosis (MS) is the most common cause of chronic neurologic disability in young people. Genetic susceptibility and unidentified environmental triggers appear to be necessary in order to result in disease. MS is an extraordinarily complex trait with evidence of heterogeneity at clinical, pathologic, and therapeutic levels. Recent studies have not resolved the important question whether at a mechanistic level MS is a single disease with a wide spectrum of clinical expression, or whether it encompasses a group of separate diseases that share certain pathologic final common pathways. This question is important not only for helping to understand the causes of MS but also for designing and applying better treatments.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Compston A, ed: McAlpine’s Multiple Sclerosis, edn 4. New York: Churchill Livingston, 2005.
Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907–911.
Weinshenker BG, Bass B, Rice GP, et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133–146.
Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR: Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler 2004, 10:451–454.
Korteweg T, Tintore M, Uitdehaag B, et al.: MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006, 5:221–227.
Wilejito M, Shroff M, Buncic JR, et al.: The clinical features, MRI findings and outcome of optic neuritis in children. Neurology 2006, 67:258–262.
Tremlett H, Devonshire V: Is late-onset multiple sclerosis associated with a worse outcome? Neurology 2006, 67:954–959.
De Stefano N, Cocco E, Lai M, et al.: Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 2006, 59:634–639.
Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised dignostic criteria for neuromyelitis optica. Neurology 2006, 66:1485–1489.
Rubio JP, Bahlo M, Butzkueven H, et al.: Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Gen 2002, 70:1125–1137.
Lincoln MR, Montpetit A, Cader MZ, et al.: A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005, 37:1108–1112.
Giovannoni G, Cutter GR: Infectious causes of multiple sclerosis: contemporary criteria for causation in multiple sclerosis. Lancet Neurol 2006, 5:887–894.
Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996, 6:243–257.
Barnett MH, Sutton I: The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 2006, 19:242–247.
Bruck W, Kuhlmann T, Stadelmann C: Remyelination in multiple sclerosis. J Neurol Sci 2003, 206:181–185.
Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996, 6:259–274.
Lucchinetti C, Bruck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717.
Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458–468.
Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.
Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566–569.
Reindl M, Khalil M, Berger T: Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006, 180:50–62.
Jurewicz A, Matysiak M, Raine CS, Selmaj K: Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007, 68:283–287.
Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606–616.
Coles AJ, Wing MG, Molyneux P, et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296–304.
Haegert DG: Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. Med Hypotheses 2005, 65:232–237.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heard, R.N.S. The spectrum of multiple sclerosis. Curr Allergy Asthma Rep 7, 280–284 (2007). https://doi.org/10.1007/s11882-007-0042-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11882-007-0042-y